<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8" />
<meta name="viewport" content="width=device-width, initial-scale=1" />
<title>Regular Insulin Information - Dark Theme Updated with Placeholders</title>
<style>
  @import url('https://fonts.googleapis.com/css2?family=Inter:wght@400;600;700&display=swap');

  /* Global Reset */
  *, *::before, *::after {
    box-sizing: border-box;
  }
  body {
    margin: 0;
    font-family: 'Inter', sans-serif;
    background: #0f172a; /* dark navy */
    color: #e0e7ff; /* light lavender text */
    line-height: 1.7;
    min-height: 100vh;
    display: flex;
    flex-direction: column;
  }

  a {
    color: #82c7ff;
    text-decoration: none;
    transition: color 0.3s ease;
  }
  a:hover, a:focus {
    text-decoration: underline;
    color: #38bdf8;
  }

  /* Container */
  .container {
    max-width: 1200px;
    margin: 0 auto;
    padding: 48px 24px 96px;
  }

  /* Header */
  header {
    background: linear-gradient(135deg, #1e293b, #3b82f6, #2563eb);
    color: #f0f9ff;
    padding: 36px 24px;
    position: sticky;
    top: 0;
    z-index: 1000;
    display: flex;
    align-items: center;
    gap: 20px;
    box-shadow: 0 10px 32px rgb(30 41 59 / 0.7);
    border-bottom: 1px solid #1e40af;
  }
  header img {
    height: 48px;
    width: auto;
    user-select: none;
    border-radius: 10px;
    box-shadow: 0 6px 20px rgb(59 130 246 / 0.7);
    background: #1e40af;
  }
  header h1 {
    margin: 0;
    font-weight: 700;
    font-size: 2.5rem;
    letter-spacing: 0.05em;
    user-select: none;
    line-height: 1.1;
    color: #e0e7ff;
    text-shadow: 0 0 8px rgba(59, 130, 246, 0.6);
  }

  /* Sections */
  section {
    background: #1e293b;
    border-radius: 14px;
    padding: 40px 48px;
    margin-top: 48px;
    box-shadow: 0 6px 30px rgb(99 102 241 / 0.25);
    transition: box-shadow 0.3s ease;
    color: #cbd5e1;
  }
  section:hover {
    box-shadow: 0 14px 48px rgb(96 165 250 / 0.45);
  }
  section h2 {
    margin-top: 0;
    margin-bottom: 28px;
    font-weight: 800;
    color: #93c5fd;
    border-left: 6px solid #3b82f6;
    padding-left: 16px;
    font-size: 2rem;
    letter-spacing: 0.02em;
    text-shadow: 0 0 8px #3b82f6aa;
  }
  section h3 {
    margin-top: 36px;
    margin-bottom: 18px;
    font-weight: 600;
    color: #60a5fa;
    font-size: 1.3rem;
  }
  section p, section ul, section ol {
    margin-top: 0;
    margin-bottom: 22px;
    font-size: 1.12rem;
    color: #cbd5e1;
  }

  ul {
    list-style: disc inside;
  }
  ul li, ol li {
    margin-bottom: 12px;
  }
  ol {
    list-style: decimal inside;
  }
  p strong {
    color: #93c5fd;
  }

  /* Formula Block */
  .formula {
    background: #334155;
    border-radius: 16px;
    padding: 24px 28px;
    font-family: 'Courier New', Courier, monospace;
    font-weight: 600;
    font-size: 1.3rem;
    overflow-x: auto;
    user-select: text;
    margin-top: 28px;
    color: #bfdbfe;
    box-shadow: inset 0 0 14px rgb(96 165 250 / 0.5);
  }

  /* Images container - multiple images with captions */
  .image-gallery {
    margin-top: 28px;
    display: flex;
    gap: 28px;
    justify-content: center;
    flex-wrap: wrap;
  }
  .image-card {
    background: #273449;
    border-radius: 16px;
    box-shadow: 0 8px 24px rgb(59 130 246 / 0.5);
    max-width: 320px;
    width: 100%;
    text-align: center;
    padding: 24px 16px 32px;
    transition: transform 0.3s ease;
    cursor: default;
  }
  .image-card:hover,
  .image-card:focus-within {
    transform: scale(1.04);
    outline: none;
    box-shadow: 0 16px 48px rgb(96 165 250 / 0.7);
  }
  .image-card img {
    max-width: 100%;
    height: auto;
    border-radius: 14px;
    box-shadow: 0 10px 28px rgb(59 130 246 / 0.7);
    margin-bottom: 16px;
  }
  .image-card figcaption {
    color: #a5b4fc;
    font-size: 1rem;
    font-style: italic;
    user-select: none;
  }

  /* Drug Interaction Legend */
  .interaction-legend {
    display: flex;
    flex-wrap: wrap;
    gap: 20px;
    margin-bottom: 36px;
    font-size: 1rem;
    color: #cbd5e1;
  }
  .legend-item {
    display: flex;
    align-items: center;
    gap: 12px;
  }
  .legend-box {
    width: 28px;
    height: 28px;
    border-radius: 6px;
    border: 2px solid transparent;
  }
  .no-interaction { background-color: #22c55e; border-color: #15803d; } /* bright green */
  .monitor-therapy { background-color: #fde68a; border-color: #b45309; } /* yellow */
  .avoid-combo { background-color: #fca5a5; border-color: #b91c1c; } /* red */
  .no-action { background-color: #93c5fd; border-color: #2563eb; } /* blue */
  .consider-modification { background-color: #c4b5fd; border-color: #7c3aed; } /* purple */

  /* Interaction table */
  table.interaction-table {
    width: 100%;
    border-collapse: collapse;
    margin-top: 12px;
    font-size: 1rem;
    color: #cbd5e1;
    border-radius: 12px;
    overflow: hidden;
    box-shadow: 0 10px 28px rgb(96 165 250 / 0.3);
  }
  table.interaction-table thead {
    background: #1e293b;
    color: #93c5fd;
  }
  table.interaction-table th, table.interaction-table td {
    border: none;
    padding: 14px 20px;
    text-align: left;
  }
  table.interaction-table tbody tr {
    border-bottom: 1px solid #334155;
    transition: background-color 0.3s ease;
  }
  table.interaction-table tbody tr:last-child {
    border-bottom: none;
  }
  table.interaction-table tbody tr:hover,
  table.interaction-table tbody tr:focus-within {
    background-color: #2563eb;
    color: #e0e7ff;
    outline: none;
  }

  /* Footer */
  footer {
    background: #1e293b;
    color: #a5b4fc;
    text-align: center;
    padding: 36px 24px;
    font-size: 0.9rem;
    user-select: none;
    margin-top: 64px;
    box-shadow: inset 0 1px 0 #3b82f6;
  }
  footer a {
    color: #82c7ff;
  }
  footer a:hover, footer a:focus {
    color: #38bdf8;
  }

  /* Responsive */
  @media (max-width: 1024px) {
    .container {
      padding: 40px 20px 80px;
      max-width: 720px;
    }
    section {
      padding: 28px 32px;
      margin-top: 40px;
    }
    header h1 {
      font-size: 2rem;
    }
    .image-gallery {
      gap: 20px;
    }
  }
  @media (max-width: 640px) {
    header {
      padding: 24px 16px;
      flex-direction: column;
      align-items: flex-start;
      gap: 14px;
    }
    header img {
      height: 36px;
      border-radius: 6px;
      box-shadow: 0 3px 12px rgb(59 130 246 / 0.7);
    }
    header h1 {
      font-size: 1.5rem;
      line-height: 1.2;
    }
    .container {
      padding: 32px 16px 64px;
      max-width: 100%;
    }
    section {
      padding: 24px 20px;
      margin-top: 32px;
      border-radius: 10px;
    }
    .interaction-legend {
      gap: 12px;
      font-size: 0.9rem;
    }
    .legend-box {
      width: 20px;
      height: 20px;
      border-radius: 4px;
    }
    .image-gallery {
      justify-content: center;
      gap: 18px;
    }
    .image-card {
      max-width: 280px;
      padding: 18px 12px 28px;
    }
  }
</style>
</head>
<body>
<header role="banner">
  <img src="https://storage.googleapis.com/workspace-0f70711f-8b4e-4d94-86f1-2a93ccde5887/image/785c2a86-2d40-48ff-acdd-4b18da993ca1.png" alt="Insulin vial with dark blue modern pharmaceutical label" />
  <h1>Regular Insulin: </h1>
</header>
<main class="container" role="main" aria-label="Regular Insulin detailed information">
  <section aria-labelledby="intro-title" tabindex="0">
    <h2 id="intro-title">Introduction </h2>
    <p><strong>Regular insulin</strong> is a short-acting synthetic human insulin used primarily in the management of diabetes mellitus and hyperglycemia of various etiologies. It mimics endogenous insulinâ€™s physiological effects, mainly lowering serum glucose via stimulating peripheral glucose uptake and inhibiting hepatic glucose production.</p>
    <p>This medication is available as:</p>
    <ul>
      <li>An injectable solution</li>
      <li>An intravenous (IV) solution</li>
      <li>An inhalable powder</li>
    </ul>
    <p><strong>FDA Approval:</strong> Humulin, the first biosynthetic human insulin, was approved on October 28, 1982, after five months of review.</p>
    <div class="formula" aria-label="Protein chemical formula and molecular weight">
      C<sub>257</sub>H<sub>383</sub>N<sub>65</sub>O<sub>77</sub>S<sub>6</sub> &mdash; Molecular Weight: 5808 Da
    </div>
  </section>

  <section aria-labelledby="images-title" tabindex="0">
    <h2 id="images-title">Insulin Vials and Injection Images</h2>
    <div class="image-gallery" role="list">
      <figure class="image-card" role="listitem" tabindex="0">
        <img src="https://storage.googleapis.com/workspace-0f70711f-8b4e-4d94-86f1-2a93ccde5887/image/9fb48dec-e6c2-4e0d-843b-256a47d8d61d.png" alt="Placeholder image of Humulin R vial pharmaceutical packaging shown in close-up" />
        <figcaption>Humulin R Vial</figcaption>
      </figure>
      <figure class="image-card" role="listitem" tabindex="0">
        <img src="https://storage.googleapis.com/workspace-0f70711f-8b4e-4d94-86f1-2a93ccde5887/image/2f422f60-06f9-4d8d-8277-f0ed1eda3a3a.png" alt="Placeholder image of syringe with insulin injection suitable for diabetes treatment" />
        <figcaption>Insulin Injection Syringe</figcaption>
      </figure>
    </div>
  </section>

  <section aria-labelledby="indications-title" tabindex="0">
    <h2 id="indications-title">Indications</h2>
    <p><strong>Labeled Uses:</strong> Mainstay therapy for diabetes mellitus type 1 and some cases of type 2 to improve glycemic control.</p>
    <p><strong>Off-label Uses Include:</strong></p>
    <ul>
      <li>Hormonal resuscitation in cadaveric organ recovery</li>
      <li>Treatment of calcium channel blocker and beta-blocker toxicity</li>
      <li>Management of severe hyperglycemia and diabetic ketoacidosis (continuous IV infusion dosing guidance included)</li>
      <li>Refractory gestational diabetes mellitus</li>
      <li>Management of hyperkalemia (IV insulin with dextrose)</li>
    </ul>
  </section>

  <section aria-labelledby="pharmacology-title" tabindex="0">
    <h2 id="pharmacology-title">Pharmacology</h2>
    <h3>Mechanism of Action</h3>
    <p>Stimulates peripheral glucose uptake (skeletal muscle and fat), inhibits hepatic glucose production, lipolysis, and proteolysis, and enhances protein synthesis targeting skeletal muscle, liver, and adipose tissue.</p>

    <h3>Pharmacokinetics</h3>
    <ul>
      <li><strong>Absorption:</strong> Bioavailability 55-77% (subcutaneous), onset 0.5 hr, peak 0.8-2 hr, duration 4â€“12 hrs (U-100), up to 24 hrs (U-500)</li>
      <li><strong>Distribution Volume:</strong> 0.26-0.36 L/kg</li>
      <li><strong>Metabolism:</strong> Liver (&gt;50%), kidney (~30%), adipose tissue/muscle (~20%)</li>
      <li><strong>Excretion:</strong> Urine</li>
    </ul>
  </section>

  <section aria-labelledby="clinical-use-title" tabindex="0">
    <h2 id="clinical-use-title">Clinical Use &amp; Administration</h2>
    <p><strong>Why mostly used in Type 1 Diabetes?</strong></p>
    <p>Type 1 Diabetes is caused by autoimmune destruction of pancreatic beta cells, resulting in insulin deficiency. People with T1D rely primarily on exogenous insulin to manage blood glucose levels.</p>
    <p><strong>Administration Guidelines:</strong></p>
    <ol>
      <li><strong>Preparation:</strong> Ensure insulin solution is clear and colorless. Do not use if cloudy or viscous.</li>
      <li><strong>Injection:</strong> Administer subcutaneously at a 90Â° angle using a suitable insulin syringe or pen.</li>
      <li><strong>Intravenous Use:</strong> Use U-100 insulin only. Monitor serum potassium and blood glucose closely during infusion.</li>
      <li><strong>Dosing:</strong> Follow prescribed dosage exactly; avoid dosing without meals to prevent hypoglycemia.</li>
      <li><strong>Storage of opened vials and pens:</strong> Follow temperature guidelines to maintain efficacy.</li>
      <li><strong>Disposal:</strong> Dispose of needles and pens safely to avoid injury or contamination.</li>
    </ol>
    <p><strong>Additional Administration Steps (Humulin R):</strong></p>
    <ol>
      <li>Choose appropriate syringe or insulin pen compatible with Humulin R.</li>
      <li>Inspect the vial or pen for clarity and expiration date; do not use if cloudy or past expiry.</li>
      <li>Wash hands and clean injection site with alcohol swab.</li>
      <li>If using a vial, roll it gently between palms to mix insulin; do not shake.</li>
      <li>Draw up the correct dose by inserting needle into vial and pulling plunger slowly.</li>
      <li>Remove air bubbles from syringe by flicking and pushing air out.</li>
      <li>Pinch skin to create a fold and inject subcutaneously at 90-degree angle.</li>
      <li>Hold needle in place for 5-10 seconds before withdrawal to ensure full dose delivery.</li>
      <li>Dispose of syringe or pen needle in proper sharps container.</li>
      <li>Rotate injection sites to avoid lipodystrophy.</li>
      <li>Monitor blood glucose regularly per medical advice.</li>
    </ol>
  </section>

  <section aria-labelledby="storage-title" tabindex="0">
    <h2 id="storage-title">Storage Instructions</h2>
    <h3>Humulin R U-100</h3>
    <ul>
      <li>Unopened vials: Refrigerate 2-8Â°C (36-46Â°F) until expiration or store room temperature max 31 days; Do not freeze</li>
      <li>Opened vials: Refrigerate or room temperature â‰¤30Â°C (86Â°F) for up to 31 days; do not freeze</li>
    </ul>
    <h3>Humulin R U-500</h3>
    <ul>
      <li>Unopened vials: Refrigerate 2-8Â°C until expiration; can store at room temperature &lt;30Â°C (86Â°F) for 40 days; do not shake vial</li>
      <li>Opened vials: Refrigerate or room temperature â‰¤30Â°C, discard after 40 days</li>
    </ul>
    <h3>Humulin R KwikPen</h3>
    <ul>
      <li>Unopened pens: Refrigerate 2-8Â°C until expiration; or keep room temperature â‰¤30Â°C for max 28 days; protect from heat and light; do not freeze</li>
      <li>Used pens: Store room temperature â‰¤30Â°C, discard after 28 days; do not refrigerate</li>
    </ul>
    <h3>Novolin R Vials</h3>
    <ul>
      <li>Unopened: Refrigerate 2-8Â°C until expiration or room temperature â‰¤25Â°C (77Â°F) max 42 days; do not freeze</li>
      <li>Opened: Store at room temperature â‰¤25Â°C; refrigeration not recommended</li>
    </ul>
  </section>

  <section aria-labelledby="pregnancy-title" tabindex="0">
    <h2 id="pregnancy-title">Pregnancy &amp; Lactation Considerations</h2>
    <p><strong>Pregnancy Category B</strong>: No established association with birth defects or adverse outcomes. Poorly controlled diabetes in pregnancy poses risks to both mother and fetus.</p>
    <p>Lactation studies show exogenous insulin transfers into breast milk but no adverse effects reported in infants.</p>
  </section>

  <section aria-labelledby="side-effects-title" tabindex="0">
    <h2 id="side-effects-title">Side Effects &amp; Adverse Reactions</h2>
    <ul>
      <li>Hypersensitivity/allergic reactions (redness, swelling, rash, breathing difficulty)</li>
      <li>Swelling (edema), weight gain</li>
      <li>Injection site reactions (pruritus, erythema, skin thickening or hollowing)</li>
      <li>Hypokalemia (potassium shift causing cramps, arrhythmias)</li>
      <li>Hypoglycemia (life-threatening if improper dosing)</li>
      <li>Cardiovascular: peripheral edema</li>
    </ul>
  </section>

  <section aria-labelledby="contraindications-title" tabindex="0">
    <h2 id="contraindications-title">Contraindications &amp; Drug Interactions</h2>
    <p><strong>Contraindications:</strong> Known hypersensitivity to insulin.</p>
    <p><strong>Drug Interactions Summary:</strong> The following table summarizes interaction types between regular insulin and various drugs or agents as per Lexidrug interaction classification:</p>

    <div class="interaction-legend" aria-label="Legend for drug interaction categories">
      <div class="legend-item"><div class="legend-box no-interaction" aria-hidden="true"></div> No known interaction</div>
      <div class="legend-item"><div class="legend-box monitor-therapy" aria-hidden="true"></div> Monitor therapy</div>
      <div class="legend-item"><div class="legend-box avoid-combo" aria-hidden="true"></div> Avoid combination</div>
      <div class="legend-item"><div class="legend-box no-action" aria-hidden="true"></div> No action needed</div>
      <div class="legend-item"><div class="legend-box consider-modification" aria-hidden="true"></div> Consider therapy modification</div>
    </div>
    
    <table class="interaction-table" aria-describedby="interaction-desc" role="grid" tabindex="0">
      <caption id="interaction-desc" class="sr-only">Drug interactions for Regular Insulin</caption>
      <thead>
        <tr>
          <th scope="col">Drug or Agent</th>
          <th scope="col">Interaction Type</th>
        </tr>
      </thead>
      <tbody>
        <tr><td>Macimorelin</td><td><span class="legend-box avoid-combo" aria-hidden="true"></span> Avoid combination</td></tr>
        <tr><td>Rosiglitazone</td><td><span class="legend-box monitor-therapy" aria-hidden="true"></span> Monitor therapy</td></tr>
        <tr><td>Alpha-Glucosidase Inhibitors</td><td><span class="legend-box no-action" aria-hidden="true"></span> No action needed</td></tr>
        <tr><td>Dipeptidyl Peptidase-IV Inhibitors</td><td><span class="legend-box no-interaction" aria-hidden="true"></span> No known interaction</td></tr>
        <tr><td>Glucagon-Like Peptide-1 Agonists</td><td><span class="legend-box monitor-therapy" aria-hidden="true"></span> Monitor therapy</td></tr>
        <tr><td>Liraglutide</td><td><span class="legend-box monitor-therapy" aria-hidden="true"></span> Monitor therapy</td></tr>
        <tr><td>Metreleptin</td><td><span class="legend-box consider-modification" aria-hidden="true"></span> Consider therapy modification</td></tr>
        <tr><td>Pioglitazone</td><td><span class="legend-box monitor-therapy" aria-hidden="true"></span> Monitor therapy</td></tr>
        <tr><td>Pramlintide</td><td><span class="legend-box no-action" aria-hidden="true"></span> No action needed</td></tr>
        <tr><td>Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors</td><td><span class="legend-box avoid-combo" aria-hidden="true"></span> Avoid combination</td></tr>
        <tr><td>Alpha-Lipoic Acid</td><td><span class="legend-box no-action" aria-hidden="true"></span> No action needed</td></tr>
        <tr><td>Antidiabetic Agents</td><td><span class="legend-box monitor-therapy" aria-hidden="true"></span> Monitor therapy</td></tr>
        <tr><td>Androgens</td><td><span class="legend-box avoid-combo" aria-hidden="true"></span> Avoid combination</td></tr>
        <tr><td>Beta-Blockers (Beta1 Selective)</td><td><span class="legend-box monitor-therapy" aria-hidden="true"></span> Monitor therapy</td></tr>
      </tbody>
    </table>
    <p>Note: Clinicians should use judgment based on up-to-date information and individual patient contexts when managing these interactions.</p>
  </section>

  <section aria-labelledby="toxicity-title" tabindex="0">
    <h2 id="toxicity-title">Toxicity &amp; Antidote</h2>
    <p>Insulin toxicity symptoms relate to hypoglycemia and electrolyte disturbances, possibly causing seizures, coma, hypotension, bradycardia.</p>
    <p><strong>Antidote:</strong> Dextrose infusion (400-600 mg/kg/hr) and glucagon emergency kit with dextrose for severe toxicity.</p>
  </section>

  <section aria-labelledby="pen-device-title" tabindex="0">
    <h2 id="pen-device-title">Pen Device</h2>
    <p><strong>Humulin R KwikPen:</strong> First FDA-approved prefilled pen device for U-500 strength insulin (500 units/mL) for patients needing &gt;200 units/day.</p>
    <p><strong>Additional Pen Device Information:</strong></p>
    <ol>
      <li>Humulin R KwikPen allows accurate dosing with easy-to-read increments.</li>
      <li>Prefilled and disposable pen designed for patient convenience.</li>
      <li>Features a robust and ergonomic design for easy handling.</li>
      <li>Requires no mixing or reconstitution prior to use.</li>
      <li>Has a maximum dose per injection of 300 units.</li>
      <li>Should be stored between 2â€“8Â°C before first use and can be kept at room temperature (below 30Â°C) for 28 days after first use.</li>
      <li>Proper disposal of the pen and needles is mandatory to prevent injury.</li>
    </ol>
  </section>

  <section aria-labelledby="inhalation-insulin-title" tabindex="0">
    <h2 id="inhalation-insulin-title">Inhalation Insulin</h2>
    <p><strong>Afrezza:</strong> Afrezza is an FDA-approved inhaled short-acting insulin powder delivered via a small inhaler device. It is prescribed for adults to improve glycemic control in diabetes mellitus.</p>
    <p>Warning: Afrezza should not be used in patients with chronic lung disease such as asthma or COPD due to the risk of acute bronchospasm.</p>
    <p>Typical dosing duration is 15 minutes before meals. Patients require pulmonary function testing prior to initiation and periodically during therapy.</p>
    <p>Storage: Store unopened cartridges refrigerated; opened packs can be kept at room temperature for up to 10 days.</p>
    <div class="image-section" role="img" aria-label="Photo of Afrezza inhaler device and packaging">
      <img src="https://storage.googleapis.com/workspace-0f70711f-8b4e-4d94-86f1-2a93ccde5887/image/da53f6ca-d856-49a9-b6b7-d17db49b5dd7.png" alt="Afrezza inhaler device and packaging used for inhaled insulin therapy" />
      <figcaption>Afrezza inhaler device and packaging used for inhaled short-acting insulin delivery.</figcaption>
    </div>
  </section>

  <section aria-labelledby="references-title" tabindex="0">
    <h2 id="references-title">References</h2>
    <ul>
      <li><a href="https://www.ncbi.nlm.nih.gov/books/NBK553094/" target="_blank" rel="noopener noreferrer">NCBI Bookshelf - Insulin Overview</a></li>
      <li><a href="https://www.medscape.com" target="_blank" rel="noopener noreferrer">Medscape.com</a></li>
      <li><a href="https://www.drugbank.ca" target="_blank" rel="noopener noreferrer">Drug Bank</a></li>
      <li><a href="https://www.drugs.com" target="_blank" rel="noopener noreferrer">Drugs.com</a></li>
      <li><a href="https://www.lexicondrugs.com/" target="_blank" rel="noopener noreferrer">Lexicom.Drugs - Drug Interactions</a></li>
      <li><a href="https://www.fda.gov" target="_blank" rel="noopener noreferrer">FDA Articles</a></li>
    </ul>
  </section>
</main>
<footer>
  &copy; 2025 Regular Insulin Reference | 
</footer>
</body>
</html>

